Verywell Health on MSN1mon
Spravato Nasal Spray Can Now Be Used Alone for Treatment-Resistant Depression
The Food and Drug Administration (FDA) has expanded its approval of a ketamine nasal spray, Spravato (esketamine), as a ...
pharmaphorum5d
J&J’s Spravato for depression ‘should be much cheaper’
Johnson & Johnson has priced its new Spravato nasal spray for treatment-resistant depression (TRD) too high to offer value for money, says a US cost-effectiveness body. The Institute for Clinical ...
pharmaphorum4y
NICE rejects Janssen's depression spray Spravato for second time
Spravato is approved as an adjunctive therapy administered by a nasal spray and is based on esketamine, a form of the drug ketamine, an anaesthetic commonly used illegally for recreational purposes.
Business Insider6y
Regulators just approved the first new depression drug since the 1980s, and some see blockbuster potential
Called Spravato, a brand name for esketamine, and developed by Johnson & Johnson, the drug is a nasal spray designed to treat severe forms of depression that don't respond to other medications.
Benzinga.com29d
Psychedelics-Focused Compass Pathways Has Established Itself As 'Credible CNS Biotechnology Company,' Analyst Says
Stifel initiated coverage on Compass Pathways with a Buy rating and an $11 price ... 2.0. Johnson & Johnson’s JNJ Spravato (esketamine) is a nasal spray for TRD and major depressive disorder ...